FibroGen’s stock skyrockets upon the positive results of a new study
Used to ta...
Biotech company FibroGen stock has soared by over 50% upon the positive results of new lung disease drug pamrevlumab within clinical trials.
Used to tackle lung disease idiopathic pulmonary fibrosis, the company has recently completed FDA tests, at which these positive results will provide significant revenue increases for the company, adding $3 to $4 billion to its market cap to “eventually $35 to $50 to its share price,” CNBC has reported.
Idiopathic pulmonary fibrosis leads to severe scarring on the lungs, which impacts on oxygen which can be transferred into a patient’s bloodstream. The disease leads to severe breathing problems and high mortality rates, with five years granted post prognosis.
Pamrevlumab has been described by FibroGen as a “monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). CTGF is a common factor in chronic fibrotic and proliferative disorders, characterized by persistent and excessive fibrous tissue which can lead to organ dysfunction and failure, and in cancer, by promotion of tumour growth.
- Organ transplants are becoming accessible in the UAE
- CRISPR is now used to edit mutations which cause heart failure
- Apollo Hospitals: Personalizing healthcare with technology
Pamrevlumab is used for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD).”
Completing Phase 2 will lead to the third phase in clinical trials, which could lead to potential breakthroughs in treatment. The trials saw participants take pamrevlumab or placebo for up to 48 weeks.
“We are very encouraged by the top line IPF Phase 2 clinical study results that we announced today, in which pamrevlumab-treated patients had a significantly lower rate of decline in lung function, as compared to the placebo-treated patients,” commented FibroGen CEO Thomas B. Neff. “In addition, pamrevlumab continued to be well tolerated as a monotherapy in this IPF study, and was well tolerated in combination with pirfenidone and nintedanib.
We believe that the promising outcomes of these studies enable us to advance pamrevlumab into Phase III clinical development.”
NHS trials test that predicts sepsis 3 days in advance
A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England.
Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year.
The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time.
From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.
Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction.
Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.
The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years.
If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.
Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”